BioSpace News Archive

Agrees with ISS that “Board Level Change is Warranted, With the Ultimate Goal of Enhancing Shareholder Board Oversight” Urges Stockholders to Vote Before Thursday, July 11 Annual Meeting

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that based on recent meetings with health authorities in the U.S. and Europe, the company plans to submit marketing applications to both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 4Q 2019 for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A.

Compass Therapeutics announced the first patient has been dosed in its multi-center, open-label, first-in-human Phase 1 trial of CTX-471, a fully human monoclonal antibody that binds and activates a unique epitope of the co-stimulatory receptor CD137 expressed on T cells and NK cells.

Mr. Michael Lisjak as Global Head of Regulatory Affairs and Senior Vice President for Business Development.

Lygos driving to provide sustainable Bio-DEM product at 5-20 kta scale needed for projected new product growth

OneOncology and AmerisourceBergen to Support Community Oncology Practices to Provide High-Quality Cancer Care to Patients Across the Nation

Noted Patient Safety Advocate and Top Hospital System CIO to offer expertise and guidance as MedAware expands U.S. footprint

The acquisition is a stepping stone for Eurofins into the luxury textile industry with a renowned and well-established partner

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulvar intraepithelial neoplasia (VIN).

Battelle will play a key role for NASA by running a nationwide contest giving K-12 students in United States schools a chance to name the Mars 2020 Rover.